# Fund: United-i Global Balanced Fund

As at 30 September 2022

#### **Performance Review**

For the month of September, the Fund MYRH class registered a return of -7.57%.

#### **Equity**

Strong selection in health care, materials and consumer discretionary was partially offset by selection in information technology. On a regional basis, strong stock selection in Developed EU & Middle East ex UK and North America was partially offset by selection in Japan and Emerging Markets.

Within health care and materials, our top relative contributors were overweights to Eli Lilly and Vale, respectively. Within information technology and financials, our top relative detractors were overweights to Advanced Micro Devices and S&P Global, respectively.

Eli Lilly shares rose after Eisai and Biogen reported breakthrough trial results for their Alzheimer's drug. The news bodes well for Eli Lilly's drug donanemab, which also targets removing the amyloid beta protein to slow disease progression. Donanemab's readout is slated for 2Q23. The US FDA also approved the company's oral lung cancer drug, Retevmo, for certain adult patients with solid tumors with a specific genetic makeup. Shares of Advanced Micro Devices fell sharply during the month after the August Consumer Price Index data release showed greater-than-expected inflation. The US Federal Reserve consequently raised interest rates by 0.75%. Investors in the semiconductor space remain concerned over the increased cost of borrowing, rising inflation, a potential decrease in demand and the likelihood of a recession.

#### Sukuk

Overall, the sukuk sleeves registered -3.34% return whilst the benchmark is at -3.58%. The Sukuk sleeves outperformed its benchmark driven by government-related sector, the outperformance were driven by our strong conviction is sector allocation. MGII 10/32 was the main detractor whereas Soq Sukuk 3.241% 18/01/2023 were the main contributor.

We will continue remain defensive in our portfolio strategy to ensure desirable return to the portfolio. We will be steadfast in our credit exposure where GCC region accounted by 44.11%, Saudi Arabia (SA) (18.78%), United Arab Emirates (UAE) (20.21%), Qatar (3.98%) and Kuwait (1.23%). Our exposure in Malaysia and Indonesia are at 41.40% and 14.49% respectively.

#### **Strategy Moving Forward**

The fund will continue to be neutral in its asset allocation. Due to market volatility, we will continue to be defensive in our investment theses. We do not expect any significant changes and will continue to monitor both asset classes for any opportunities that may arise from market volatility.

#### **Equity**

From a regional perspective, our largest overweight was North America and we were most underweight to Emerging Markets.



#### Sukuk

Going forward, we expect local debt market to remain volatile and trade in a cautious mode as the US Fed remains hawkish. Additionally, market would turn its attention to the upcoming Budget 2023, which will be tabled on 7 October. We will be remain defensive in our sukuk selection and be vigilant before making any decision to mobilise our cash holdings.

**Holdings Commentary** 

Stocks	Country	Sector	Remarks		
Eli Lilly	United States	Health Care	<ul> <li>Eli Lilly is a diversified large-cap biopharmaceutical company with multiple drivers of growth, including diabetes, autoimmune diseases, and central nervous system (CNS) diseases.</li> <li>Eli Lilly shares rose after Eisai and Biogen reported breakthrough trial results for their Alzheimer's drug.</li> <li>We think the news bodes well for Eli Lilly's drug donanemab, which also targets removing the amyloid beta protein to slow disease progression.</li> <li>Donanemab's readout is slated for 2Q23.</li> <li>The US FDA also approved the company's oral lung cancer drug, Retevmo, for certain adult patients with solid tumors with a specific genetic makeup.</li> <li>We continue to like Eli Lilly in the large-cap pharma space.</li> </ul>		
Advanced Micro Devices	United States	Information Technology	<ul> <li>Advanced Micro Devices is a US based semiconductor manufacturer.</li> <li>Shares of Advanced Micro Devices fell sharply during the month after the August Consumer Price Index data release showed greater-than-expected inflation.</li> <li>The US Federal Reserve consequently raised interest rates by 0.75%.</li> <li>Investors in the semiconductor space remain concerned over the increased cost of borrowing, rising inflation, a potential decrease in demand and the likelihood of a recession.</li> <li>Advanced Micro Devices' fundamentals are very strong and the company is benefitting from strong demand for semiconductors.</li> <li>We anticipate future revenue growth will also be driven by accelerated market share gains in the server and PC businesses and continued strength in their gaming consoles business.</li> </ul>		



Sukuk	Country	Sector	Remarks		
SA Global Sukuk Ltd	Saudi Arabia	Sovereign	<ul> <li>Saudi Aramco is officially known as Saudi Arabian Oil Company and a public petroleum and natural gas company based in Dhahran.</li> <li>It is one of the largest companies in the world by revenue and has both the world's second-largest proven crude oil reserves and largest daily oil production of all oil-producing companies.</li> </ul>		
Malaysia Government Investment Issue	Malaysia	Sovereign	• A country in Southeast Asia with federal constitutional monarchy consists of 13 states and three federal territories, separated by the South China Sea into two regions, Peninsular Malaysia and Borneo's East Malaysia.		

## Asset Allocation as at 30 September 2022

Asset Class	% Wgt
Equity	47.84%
Sukuk	45.53%
Cash	6.63%

## Top 5 Holdings as at 30 September 2022

Equity		Sukuk		
Top 5 Holdings	%	Top 5 Holdings	%	
MICROSOFT ORD	1 2.85	GII MURABAHAH 1/2022 4.193% 07.10.2032	1.67	
APPLE ORD	) 84	GII MURABAHAH 1/2020 3.422% 30.09.2027	1.62	
AMAZON COM ORD	2.29	GII MURABAHAH 2/2020 3.465% 15.10.2030	1.58	
ALPHABET CL A ORD	1.13	KSA SUKUK 2.969% 29.10.2029	1.40	
ELI LILLY ORD	0.85	SAUDI ELECTRICITY GLOBAL SUKUK 4.723% 27.09.2028	1.15	



# **Characteristic of Sukuk Portfolio as at 30 September 2022 Income Distribution**

	Cumulative YTD	25 May 2022
MYR Hedged Class	2.67%	2.67%
USD Class	1.06%	1.06%
AUD Hedged Class	2.73%	2.73%

Sukuk (YTD)			
Duration	3.84		
Yield %	4.20		
Avg credit rating	A3		

#### **Fund Classes**

Fund Classes						
AUD Hedged	GBP Hedged	MYR Class	MYR Hedged	RMB Hedged	SGD Hedged	USD Class
Class	Class		Class	Class	Class	



### **Important Notice and Disclaimers**

This information shall not be copied, or relied upon by any person for whatever purpose. The information herein is given on a general basis without obligation and is strictly for information only.

These documents are for general information only and do not take into account your objectives, financial situations or needs. These slides are not an offer, solicitation, recommendation or advice to buy or sell any investment product, including any collective investment schemes or shares of companies mentioned within. The information contained in these slides, including any data, projections and underlying assumptions are based upon certain assumptions, management forecasts and analysis of information available and reflects prevailing conditions and our views as of the date of the document, all of which are subject to change at any time without notice.

You should be aware that investments carry risks. Please consider the fees and charges involved before investing. UOB Asset Management (Malaysia) Berhad does not guarantee any returns on the investments.

In preparing these slides, UOBAM(M) has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources or which was otherwise reviewed by UOBAM(M). UOBAM(M) does not warrant the accuracy, adequacy, timeliness or completeness of the information herein for any particular purpose, and expressly disclaims liability for any error, inaccuracy or omission. UOBAM(M) and its employees shall not be held liable for any decision or action taken based on the views expressed or information contained within this publication. Any opinion, projection and other forward looking statement regarding future events or performance of, including but not limited to, countries, markets or companies is not necessarily indicative of, and may differ from actual events or results. Nothing in this publication constitutes accounting, legal, regulatory, tax or other advice. The information herein has no regard to the specific objectives, financial situation and particular needs of any specific person. You may wish to seek advice from a professional or an independent financial adviser about the issues discussed herein or before investing in any investment product. Should you choose not to seek such advice, you should consider carefully whether the investment or product is suitable for you or your organization.

UOB Asset Management (Malaysia) Berhad (Company No. 199101009166 (219478-X))

